NEW YORK (GenomeWeb News) — Pharmacogenomics test developer MolecularMD has reeled in $3 million in financing from the Ballast Point Ventures, according to the St. Petersburg, Fla.-based venture capital firm.

MolecularMD is focused on developing molecular diagnostic tests to speed clinical development and regulatory approval of cancer therapies. The company's first tests were associated with imatinib (Gleevec), Novartis' treatment for chronic myelogenous leukemia, and it plans to expand into other cancer areas, including colon and lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.